Cogent Biosciences Inc Aktie News

According to a Form 4, one Cogent Biosciences insider sold 65,000 shares of the biotech on Dec. 26 for a total value of $2.52 million. This sale represented 37.27% of Evan Kearns's direct holdings, as reported, reducing direct ownership to 109,398 shares.

WALTHAM, Mass. and BOULDER, Colo., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, President and Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 202...

The biotech's chief legal and financial officers were among four executives who sold shares on the same day.

WALTHAM, Mass. and BOULDER, Colo.

Cogent Biosciences, Inc. (COGT) Discusses Full SUMMIT and Positive APEX Trial Results in Systemic Mastocytosis at ASH Conference Transcript

-- Bezuclastinib achieves clear clinical benefit across all symptom domains including significant improvements on 11 individual symptoms plus the most severe symptom at baseline -- -- Bezuclastinib demonstrates that reducing objective measures of disease, including serum tryptase, correlates with improvement in symptom severity; the first time this has been shown in NonAdvSM patients --

The biotech sector began December with notable weakness, as both IBB and XBI ETFs declined over two percent during trading on Monday.  The sector has bounced back since. However, small biotech stocks have been on a huge run since mid-September, due primarily to a notable uptick in M&A activity across the industry. Numerous small and midcap biotech/biopharma stocks have been purchased for signif...

WALTHAM, Mass. and BOULDER, Colo., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its participation in the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025 at 11:30 a.m. GMT (6:30 a.m. ET).